Cancer treatment Autoimmune therapy

Mitaka Healthcare Clinic is a medical clinic that provides innovative healthcare by advancing both general internal medicine and regenerative medicine.

In diagnosing lifestyle-related diseases, the clinic does not rely solely on blood tests. Instead, it actively incorporates ultrasound imaging to visualize the actual changes occurring inside the body and guide treatment.

For example, patients with high cholesterol undergo vascular ultrasound to evaluate the condition of arteriosclerosis. Those with high triglyceride levels can be assessed for fatty liver using ultrasound imaging. In addition, patients with high uric acid levels can undergo ultrasound examinations to evaluate the risk of gout and detect signs of inflammation.

By combining blood test data and imaging findings, the clinic provides more precise and comprehensive medical care.

In cancer treatment, the clinic offers immune cell therapies, such as ANK therapy and dendritic cell therapy, providing advanced cancer treatment tailored to each patient.

The clinic is located in Mitaka, about 20 minutes by train from Shinjuku Station. Situated in a calm residential area of Tokyo, it provides a comfortable environment where patients can receive treatment in a relaxed setting.

Location

〒1810013
3-38-4, Shimorenjaku, Mitaka-shi

Facility Overview

【Location】
Mitaka City, Tokyo
Within 9 minutes on foot from Mitaka Station (JR Chuo Line / Sobu Line)
Approximately 21 minutes by train from Shinjuku Station

【Medical Equipment】

Ultrasound diagnostic system

Electrocardiogram (ECG)

Chest and abdominal X-ray

【Medical Services】

Lifestyle-related diseases (hypertension, diabetes, hyperlipidemia, hyperuricemia)

Thyroid diseases

Regenerative medicine (immune cell therapy)

Kampo (traditional Japanese herbal medicine) internal medicine

【Staff】

Physicians: 1 full-time, 2 part-time

Nurses: 4 full-time

Medical laboratory technologist: 1 full-time

Administrative staff: 2 full-time, 2 part-time

【Other Facilities】

Pharmacy available on-site (partner company)

Specialty

【Medical Services for International Patients】

＜Target Diseases and Conditions＞

Various solid tumors (such as lung cancer, gastric cancer, colorectal cancer, pancreatic cancer, breast cancer, and prostate cancer)

Recurrent or metastatic cancer

Recurrence prevention and long-term management after standard treatments

＜Therapies and Procedures＞

Immune memory–inducing dendritic cell therapy

Treatments aimed at improving the patient's physical condition and the tumor microenvironment

Available Programs

• Mitaka Healthcare Clinic　　　 Immune Memory–Inducing Dendritic Cell Therapy

  Immune Memory–Inducing Dendritic Cell Therapy

  【Target Patients】 Patients with all types of solid tumors Immune Memory–Inducing Dendritic Cell Therapy is an advanced personalized cancer immunotherapy designed to train the patient’s own immune system to recognize and remember cancer cells. In principle, dendritic cell therapy is administered as a single treatment course. In this treatment, monocytes are collected from the patient’s blood and cultured and activated into dendritic cells, which act as key regulators of immune responses. These dendritic cells are prepared to present tumor antigens and are then returned to the patient’s body. Once administered, two types of T cells—cytotoxic T lymphocytes (CTLs), which directly attack cancer cells, and helper T cells—are activated. These T cells work cooperatively to recognize and destroy cancer cells. Additionally, the therapy aims to promote the formation of immune memory, enabling the immune system to respond rapidly if the cancer recurs. For dendritic cell therapy to function effectively, alkalization of the body and antioxidant therapy are considered important. Therefore, treatments aimed at improving the patient’s constitution and the tumor microenvironment are also provided. While conventional treatments mainly focus on reducing tumor size, our immune memory–inducing dendritic cell therapy aims to educate the immune system and establish a long-term cancer surveillance mechanism, supporting the patient’s potential for long-term survival.

  View Details